There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MiMedx Group (MDXG – Research Report) and Repligen (RGEN – Research Report) with bullish sentiments.
MiMedx Group (MDXG)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on MiMedx Group. The company’s shares closed last Monday at $6.32.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiMedx Group with a $11.67 average price target, implying an 87.0% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Repligen (RGEN)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Repligen. The company’s shares closed last Monday at $114.17, close to its 52-week low of $110.45.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Repligen with a $196.50 average price target, which is a 61.4% upside from current levels. In a report issued on October 17, J.P. Morgan also maintained a Buy rating on the stock with a $180.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDXG:
- MIMEDX Announces Third Quarter 2023 Operating and Financial Results
- MiMedx Group Inc. (MDXG) Q3 Earnings Cheat Sheet
- Roblox upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Craig-Hallum sees MiMedx becoming ‘THE wound care company,’ starts at Buy
- MiMedx announces launch of EPIEFFECT
